小剂量地西他滨治疗骨髓增生异常综合征临床效果观察

Clinical observation on the treatment of myelodysplastic syndrome with low dose of Decitabine

目的观察小剂量地西他滨治疗骨髓增生异常综合征的临床效果。方法选择2014年1月-2016年12月骨髓增生异常综合征患者30例,均给予地西他滨10~20 mg·m-2·d-1静脉输注3 h,连续应用5 d,28 d为1个周期,观察其治疗效果及不良反应。结果治疗效果:完全缓解3例(10.00%),部分缓解14例(46.67%)、未缓解13例(43.33%),总缓解率为56.67%。不良反应:骨髓抑制(白细胞减少)2例(6.67%),恶心6例(20.00%),发热2例(6.67%),肝功能异常3例(10.00%),不良反应总发生率为43.33%,所有不良反应在停药或降低药量后有所减少,未并发严重感染、脏器功能衰竭等严重不良反应。结论小剂量地西他滨治疗骨髓增生异常综合征完全缓解及部分缓解率高,药物不良反应发生率低。

Objective To observe the clinical effect of small dose of Decitabine in the treatment of myelodysplastic syndrome. Methods 30 cases of patients with myelodysplastic syndromes were selected from January 2014 to December 2016,all patients were given Decitabine 10 - 20 mg·m（-2）·d（-1） intravenous infusion 3 h,continuous application for 5 days,every 28 days for a cycle,observe the therapeutic effect and adverse reactions. Results Complete remission 3 cases（ 10. 00%）,partial remission 14 cases（ 46. 67%）,no remission 13 cases（ 43. 33%）,the overall response rate was 56. 67%. The adverse reaction of bone marrow suppression（ leukopenia） 2 cases（ 6. 67%）,nausea 6 cases（ 20. 00%）,fever 2 cases（ 6. 67%）,abnormal liver function 3 cases（ 10. 00%）,the total incidence of adverse reactions was 43. 33%. all side effects in patients with drug withdrawal or will reduce the amount after reduction,there was no serious infection rate,organ failure and other serious adverse reactions. Conclusion In the treatment of myelodysplastic syndrome,the rate of complete remission and partial remission was high,and the incidence of adverse drug reactions was low.